- Home
- CSQ vs ICUI Comparison
CSQ vs ICUI Comparison
Compare CSQ & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSQ
- ICUI
- Stock Information
- Founded
- CSQ 2003
- ICUI 1984
- Country
- CSQ United States
- ICUI United States
- Employees
- CSQ N/A
- ICUI N/A
- Industry
- CSQ Finance Companies
- ICUI Medical/Dental Instruments
- Sector
- CSQ Finance
- ICUI Health Care
- Exchange
- CSQ Nasdaq
- ICUI Nasdaq
- Market Cap
- CSQ 3.1B
- ICUI 3.0B
- IPO Year
- CSQ N/A
- ICUI 1992
- Fundamental
- Price
- CSQ $19.30
- ICUI $120.09
- Analyst Decision
- CSQ
- ICUI Buy
- Analyst Count
- CSQ 0
- ICUI 6
- Target Price
- CSQ N/A
- ICUI $179.40
- AVG Volume (30 Days)
- CSQ 220.3K
- ICUI 224.5K
- Earning Date
- CSQ 01-01-0001
- ICUI 11-06-2025
- Dividend Yield
- CSQ 7.53%
- ICUI N/A
- EPS Growth
- CSQ N/A
- ICUI N/A
- EPS
- CSQ N/A
- ICUI N/A
- Revenue
- CSQ N/A
- ICUI $2,372,504,000.00
- Revenue This Year
- CSQ N/A
- ICUI N/A
- Revenue Next Year
- CSQ N/A
- ICUI N/A
- P/E Ratio
- CSQ N/A
- ICUI N/A
- Revenue Growth
- CSQ N/A
- ICUI 2.96
- 52 Week Low
- CSQ $12.50
- ICUI $107.00
- 52 Week High
- CSQ $16.45
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- CSQ 55.86
- ICUI 48.81
- Support Level
- CSQ $19.14
- ICUI $116.21
- Resistance Level
- CSQ $19.47
- ICUI $120.60
- Average True Range (ATR)
- CSQ 0.23
- ICUI 3.70
- MACD
- CSQ 0.01
- ICUI 0.32
- Stochastic Oscillator
- CSQ 75.71
- ICUI 54.03
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.